Search

Samidorphan

, and a longer half-life, making it an attractive candidate for oral dosing. … [A235638, A235643] Samidorphan is a novel opioid antagonist structurally related to [naltrexone], with a higher affinity for opioid receptors, more potent μ-opioid receptor antagonism, higher oral bioavailability

Fexapotide

NX-1207 is an investigational new drug for BPH, whose chemical entity and mechanism of action remain undisclosed. … Nymox Pharmaceutical Corporation recently completed studies of NX-1207 for treatment of benign prostatic hyperplasia (BPH).

Berberine

It is relatively toxic parenterally, but has been used orally for various parasitic and fungal infections and as antidiarrheal.

Chlorfenson

Chlorfenson is developed by Moberg Derma for the treatment of onychomycosis (nail fungus) as the primary indication.

Lysergic acid diethylamide

Explanations in terms of LSD physically remaining in the body for months or years after consumption have been discounted by experimental evidence. … However, not all published case reports of chronic flashbacks appear to describe an anxious hyper-vigilant state reminiscent of post-traumatic stress disorder.

Luteinizing hormone

Human papillomavirus type 16 L1 capsid protein residues 2-471 antigen

Metipranolol

A beta-adrenergic antagonist effective for both beta-1 and beta-2 receptors. It is used as an antiarrhythmic, antihypertensive, and antiglaucoma agent.

Tafenoquine

[A35690] Tafenoquine was further developed collaboratively between GlaxoSmithKline and Medicines for Malaria Venture.[A35677] It was FDA approved on July 20, 2018.[L3770] … [A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.

INM005

INM005 was under investigation in clinical trials for the treatment of COVID-19. It was studied for pharmacokinetics, efficacy, and safety in a completed trial (NCT04494984). … Additionally, a retrospective cohort study investigated the effectiveness and safety of specific hyperimmune equine serum for severe hospitalized COVID-19 patients (NCT04954235)